Alpibectir
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 2, 2020 (NCT04654143)
Timeline
Indications
Mechanism of action
- Mycobacterium tuberculosisINHIBITOR
Mycobacterium tuberculosis inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(CCC(F)(F)F)N1CCC2(CC1)CC(C(F)(F)F)=NO2- Mol. weight
- 332.24 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095086 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05473195 | Phase 2 | Oct 31, 2022 | TASK Applied Science |
| NCT04654143 | Phase 1 | Dec 2, 2020 | BioVersys SAS, Institut de Recerca de l'HSCSP. IIB Sant Pau. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioVersys SAS | For profit | 1 | 1 | 1 | 2020 |
| Institut de Recerca de l'HSCSP. IIB Sant Pau. | Academic/Hospital | 1 | 0 | 1 | 2020 |
| TASK Applied Science | For profit | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1